Kornimate/medical-research-clean huggingface dataset:
effect of fatigue on core endurance, dynamic balance and player performance in adolescent football players

Conditions: Fatigue

Summary: the goal of this clinical study is to investigate the effect of fatigue on balance, core endurance and player performance in adolescent football players. the main questions it aims to answer are: 1. what is the effect of fatigue on balance, core endurance and player performance in adolescent football players? 2. what is the effect of balance on player performance in adolescent football players? participants will be 60 male age from 16 to 18 years selected from wadi-degla football club randomly assigned into either fatigue or control group, each player assessed for core endurance, balance and performance then fatigue protocol applied for the fatigue group and shame protocol for the control group and the repeat all measurements.

this study will be conducted in this pre and post controlled trial aiming at determining the efficacy of fatigue on core endurance, balance and player performance in adolescent football players, this study will be conducted in wadi-degla football club. players will be randomly assigned into either fatigue or control group. randomizations will be done using computer random generated numbers. fatigue group (f.g): 30 players will be assessed for core endurance, balance and performance then fatigue protocol will be applied and reasses for core endurance, balance and performance after fatigue control group (c.g): 30 players will be assessed for core endurance, balance and performance. players will be assessed at baseline and fatigue for: balance using (mft challenge disc),core endurance, 20-m running sprint and triple-hop test (tht) for perfprmace will apply rsa as fatigue protocol for the fatigue groupe. inclusion criteria: players will be included according to the eligibility criteria

Eligibility criteria:
inclusion criteria: 1. age ranges from 14 to 18 years old 2. players will selected from wadi-degla (2005, 2006 and 2007 football teams ) 3. all participants will be free from lower limb injuries for at least 6 months before the study 4. body mass index will be at optimal (18.5 to 24.9) exclusion criteria: 1. not regularly trained for at least 6 hours per week 2. major lower limb injuries for at least 6 months before the study. 3. lower limb surgery for before the study

Keywords: core endurance football balance
a study of hemopure® to enhance tissue preservation during cardiopulmonary bypass surgery

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine if hemopure® will enhance tissue preservation during cardiopulmonary bypass surgery.

the primary objective is to determine the safety and feasibility of administering hemopure® (hboc-201) to reduce myocardial necrosis, as measured by ck-mb enzyme elevation, and enhance tissue preservation during cardiopulmonary bypass.

Eligibility criteria:
inclusion criteria: * subject is between the ages of 18 and 80. * subject is an acceptable candidate for cabg. * subject is scheduled for cabg (without planned valvular repair or replacement) by cardiopulmonary bypass. * subject signs informed consent * subject and the treating physician agree that subject can comply with all study procedures and follow-up visit at time of subject screening. exclusion criteria: * pre-operative myocardial infarction, defined as ck-mb level \> 2 times upper limit of normal 24 hours prior to cabg surgery. * renal failure defined as serum creatinine greater 220 µmol/l * subject has an ejection fraction ≤ 30% (as measured by echocardiography within 30 days of study enrollment). * active infection. * history of prior stroke within last six months or history of prior stroke with residual neurological deficit. * transient ischemic attack within last 6 months. * subject has a history of coagulopathy. * subject is pregnant or currently breastfeeding. * history of allergy to beef products. * pre-operative cardiogenic shock defined as cardiac index ≤ 1.8.l/min/m2 despite the use of vasopressors. * underlying medical conditions that would limit subject's life expectancy to less than 12 months. * severe pulmonary disease \[based upon clinical diagnosis or pulmonary function tests (fev \<1 liter), if available\] that may interfere with weaning subject from ventilator. * history of acute central nervous disorder (e.g., seizure or traumatic injury). * severe hypertension (≥ 160/90 mm hg) that cannot be medically controlled despite treatment with two antihypertensive therapies. * severe liver dysfunction as defined by total bilirubin ≥ 51 µmol/l or 2 times the site normal limit of ast or alt activity. * subject has systemic mastocytosis. * subject has any condition that predisposes the subject to systemic mast cell degranulation or hypersensitivity reactions or a history of severe allergic reactions to drugs or environmental allergens. * subject has participated in another investigational drug, biologic or device study within 30 days prior to study enrollment.

Keywords: coronary artery bypass graft memory loss after cardiac surgery side effects of bypass
msc intratissular injection in crohn disease patients

Conditions: Efficacy and Safety

Summary: the main objective is to assess the efficacy of local injection of msc on the healing of refractory intestinal and perianal lesions in crohn disease. the second co-primary endpoint is safety.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age * signing the informed consent * diagnosis of crohn disease for more than 6 months * presence of at least one crohn disease lesion refractory to conventional therapies (azathioprine, 6-mercaptopurine or methotrexate) and to biologic treatments (anti-tumor necrosis factor therapies, vedolizumab, or ustekinumab). * refractory lesion defined by (1) a stricture with a length of 2 to 5cm of the colon or the ileum accessible by ileocolonoscopy (i.e. a lesion identified during a colonoscopy with a lumen narrowing non passable by the colonoscope), (2) unhealed deep ulcer of the colon or the ileum accessible to ileocolonoscopy, or (3) actively draining perianal fistula(s). * twenty patients with stricture(s), 20 patients with unhealed deep ulcer(s), and 20 patients with an actively draining perianal fistula(s) will be included exclusion criteria: * indication for immediate luminal surgery * intestinal obstruction * intra-abdominal fistulas or abscess * intestinal/colonic stricture or deep unhealed ulcer not accessible to ileocolonoscopy * undrained peri-anal abscess * pregnant women or planning pregnancy within one year * positive stool culture/toxin for clostridium difficile pathogen or other pathogens * renal failure (anuria, serious fluid overload, glomerular filtration rate \ 3 mg/dl) * documented human immunodeficiency virus infection; active hepatitis b, c, or tuberculosis * an opportunistic infection within 6 months before screening or a serious infection in the previous 3 months * malignancy within the past 5 years; or a history of lymphoproliferative disease
electrical impedance tomography of lung in child and young age

Conditions: Obstructive Lung Diseases

Summary: the investigator will determine a compliance of two diagnostic techniques (eit and body plethysmography) in collective of children and teenagers with obstructive lung disease and a matched control group.

the aim of the present study is verification of the correlation between eit-derived data and following extracted parameters of the pulmonary function: * forced expiratory volume in 1 second (fev 1) * forced vital capacity (fvc) * relative forced expiratory volume in 1 second (fev1/fvc) * maximal expiratory flow (mef 25) * total lung capacity (tlc) * resistance (raw). these findings could bring out new prospective opportunity for pulmonary function tests without cooperation. furthermore, the study aims to clarify whether eit technique can be used for regional pulmonary function testing. in addition, dynamic lung function parameter and static radiological techniques will be correlated with eit.

Eligibility criteria:
inclusion criteria: * patients: children and teenagers with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive brochitis, obstructive pneumonia). * probands: children and teenager of 5-18 years without known obstructive pulmonary diseases exclusion criteria: * active implants (icd, crt) * metal in chest * artificial heart valve * children \< 5 years * pregnant and lactating females * persons, who are in relationship of dependence to the investigator / sponsor * persons, who are not able to understand and follow the instructions of the study personnel. * lack of signed informed consent (by legal guardian /proband)

Keywords: obstructive pulmonary disease children teenager eit (electrical impedance tomography)
intravenous lidocaine infusion during video-assisted thoracic procedures for improved pain control

Conditions: Pain

Summary: the purpose of this study is to determine whether intravenous lidocaine infusion during a video-assisted chest surgery is effective in reducing the pain involved after the surgery. the hypothesis is that continuous lidocaine infusion during video-assisted thoracoscopic surgery (vats) reduces morphine consumption and postoperative pain.

despite newer surgical techniques, many patients still experience moderate to severe postoperative pain after minimally invasive surgeries. thoracoscopic surgeries are often associated with severe postoperative pain. to relieve the pain, potent narcotics have to be used, which have many side effects. surgical patients would therefore benefit from an intra-operative analgesic regimen that is safe and effective, has minimal side effects and can reduce their postoperative narcotic requirements. intravenous lidocaine has been shown previously to relieve cancer pain, chronic pain, and pain after other types of surgery.

Eligibility criteria:
inclusion criteria: * asa i-iii * age 18-75 * scheduled for vats procedure exclusion criteria: * patients receiving antiarrhythmic therapy (class ia, ib, ic) within one week of surgery * patients on preoperative analgesic therapy within one week of surgery * patients with history of drug or alcohol abuse * patients who are allergic to lidocaine * contraindication to self administered morphine (unable to understand the pca) * progression of the procedure to thoracotomy * patients who need postoperative mechanical ventilation * necessary major deviation from the intraoperative study protocol as per the discretion of the anesthesiologist in charge of the case * patients who are breastfeeding or pregnant * patient refusal

Keywords: video-assisted thoracic surgery vats lidocaine infusion vats procedures
treatment of eating disorders by physical activity and nutrition counseling

Conditions: Bulimia Nervosa; Binge Eating Disorder

Summary: "eating disorders" includes anorexia nervosa, bulimia nervosa, binge eating and other specified feeding or eating disorder (osfed). common to all is the intensively occupation to control food intake, body image and body weight. most people with this kind of disorder don't reach for professional help, or there may be more than 4 years before they do. cognitive behavior therapy is the foremost method of treatment of eating disorders, but up to 30-50% of the patients don't respond to this. the investigators find it important to identify science based alternatives of therapy, as this may reduce the health concern, and broaden the choice of therapy methods. a former study by sundgot-borgen et al in 2002, found guided physical activity to reduce symptoms of bulimia nervosa just as good as the traditional cognitive therapy. the primary objective of the project is to see whether the combination of physical exercise and dietary therapy is more effective in treating eating disorders, than cognitive therapy. secondly, the investigators want to see whether there are any differences with regard to the individual satisfaction of treatment method, and to associated costs. interviews with a sufficient number of participants from the ped-t arm to meet data saturation criteria, and all theraphists in the new treatment offer, will give uniqe insight to experiences with the treatment method and the delivery of treatment.

subjects are recruited through primary doctors, social media and newspapers, and will be included continuously by screening interviews. there will be a randomization into two treatment groups (cognitive behavior, or physical activity and nutrition education) to be followed for 16 weeks. each week includes one meeting of group therapy (90 minutes) and homework related to treatment, and for 4 weeks midway there will be two therapy meetings pr week (a total of 20 meetings). post tests are planned at week 17, and at 6, 12, and 24 months after treatment. participants reqruited during ongoing treatment groups are placed on a waitlist, serving as controls to the treatment groups.

Eligibility criteria:
inclusion criteria: * women, * bmi 17,5-35, * age of 18-40 years, * dsm-5 criteria of bulimia nervosa, * dsm-5 criteria of binge eating disorder * living nearby norwegian school of sports sciences, nsss, in oslo (norway) exclusion criteria: * age \ 40 years * bmi \ 35 * pregnancy * competing/experienced athlete * anorexia nervosa * currently, or during the past 2 years, in active treatment with cognitive therapy * other personality disturbances * suicidality

Keywords: bn binge overconsumption of food purging purge
absorption of zinc (zn) from zn-biofortified and zn-fortified maize in young zambian children between 24-36 months

Conditions: Nutritional Deficiency

Summary: the objective of this study is to compare the quantity of zn absorbed from an accurately weighed quantity (\~100 g) of minimally milled control maize (\~15 µg zn/g maize), from biofortified maize (\~30 µg zn/g) and from the same control maize that has been fortified (total level of \~60 µg zn/g) when fed to young children age 24-36 months whose major habitual food staple is maize.

participating children were randomized to receive an accurately weighed quantity of \~100g/day of either the control, fortified or biofortified study maize for 1 day. on day 1, mothers brought their child to the health center before breakfast. all meals were extrinsically labeled with a zinc stable isotope (70zn). meals on this day were consumed in the presence of the research staff. the quantities of nshima or porridge prepared and eaten were accurately weighed and duplicate meals were collected for subsequent mineral analyses. between lunch and dinner on day 1 at the health center, a blood sample was collected for hb and plasma zn analyses and, immediately after and through the same needle, a stable isotope of zinc was intravenously administered into a forearm vein over 1-2 minutes. the family then returned home. morning spot urine samples were collected twice daily starting on day 5 and continuing through day 8. once these collections were finished, the study for this child was complete. dietary zn was measured from laboratory assays of the duplicate test meals. fractional absorption of zn (faz) was measured by dual isotope tracer ratio methods in urine. absorbed zn was calculated by multiplying dietary zn by faz.

Eligibility criteria:
inclusion criteria: * children age 24 to 36 months * maize meal accounts for at least 75% energy intake * able to consume 100 g maize flour/day * clinically healthy (stunting is acceptable) * lives in target community exclusion criteria: * children with chronic or other known chronic disease * if children are receiving zinc-fortified products, these products will need to be withheld for 2 weeks prior to the study

Keywords: zinc absorption biofortification maize zambia stable isotopes of zn
clinical efficiency of xanthan hydrogels containing local anesthetics encapsulated in nanostructured lipid carries

Conditions: Dental Trauma; Local Anesthesia; Oral Cavity Disease

Summary: in a crossover, randomized, placebo-controlled, double-blind study, 40 volunteers will receive the following formulations: hydrogels containing las (local anesthetic) - lidocaine and prilocaine (both at 2.5%) encapsulated in cln (xan-cln) or not (xan-cln ), emla (topical anesthetic available on the market) and placebo hydrogel. the formulations will be applied for 2 minutes, bilaterally on the palatal mucosa (first premolar region), in two distinct sessions. soon after removal of the topical formulation, an al will be performed at the region using 0.3 ml of anesthetic solution at an injection speed of 1 ml/min. pain resulting from needle insertion and la injection will be measured using two visual analog scales (vas).

dental treatment presents numerous innovations, but the pain associated with the administration of local anesthesia (la) continuous to be a traumatic procedure for many patients. although we use topical anesthetics (ta) to reduce pain, the commercially available formulations are only effective in preventing the pain of the needle puncture. this project aims to evaluate the clinical efficacy of xanthan-based hydrogels (2%) containing las encapsulated in nanostructured lipid carriers (cln), reducing pain during puncture and injection of la in the palatine mucosa. in a crossover, randomized, placebo-controlled, double-blind study, 40 volunteers will receive the following formulations: hydrogels containing las - lidocaine and prilocaine (both at 2.5%) encapsulated in cln (xan-cln) or not (xan-cln ), emla and placebo hydrogel. the formulations will be applied for 2 minutes, bilaterally on the palatal mucosa (first premolar region), in two distinct sessions. soon after the removal of the topical formulation, an al will be performed at the region using 0.3 ml of anesthetic solution at an injection speed of 1 ml/min. the computerized morpheus® anesthetic injector will be used in order to control the variables of volume and injection speed. pain resulting from needle insertion and la injection will be measured using two visual analog scales (vas). hydrogels containing cln are expected to have good mechanical properties and allow the permeation of las efficiently through the oral mucosal epithelium. in addition, they can improve the efficacy of topical anesthesia in order to perform a painless la in the palatal mucosa.

Eligibility criteria:
inclusion criteria: * healthy participants * no lesions in the study area * have already been submitted to local anesthesia without intercurrence exclusion criteria: * used any drugs that change the pain sensibility 1 week before * smokers * alcoholic

Keywords: topical anesthesia topical formulation oral mucosa lidocaine prilocaine nanostructured lipid carrier
a multi-center rws of perampanel as an add-on treatment for epileptic seizures in chinese children

Conditions: Epilepsy

Summary: this study is a multi-center, real-word clinical trial. the purpose of this study is to evaluate the safety and effectiveness of perampanel as an add-on treatment for epileptic seizure, and to find the effective maintenance and maximum dose in chinese children. the enrolled subjects were epilepsy patients between 2 and 12 years of age who had failed clinical treatment with 1-3 anti-epileptic drugs (aeds) with the optimal dose and course of treatment and needed additional treatment. the study was a real-world prospective clinical study, and the initial and maximum doses of perampanel were individualized by neurologists according to the patient's clinical situation.

this is a multi-center, prospective, observational study. subjects who meet all of the inclusion and none of the exclusion criteria will be received perampanel. baseline seizure counts (frequency) data is collected by subjects or guardian/legally authorized representative, retrospectively. it is expected to enroll 1000 patients with epilepsy who are eligible for inclusion enrollment and receiving perampenal from july 2021 to november 2021. the initial and maximum doses of perampanel were individualized by neurologists according to the patient's clinical situation. the patients were followed up for 6 months and recorded the frequency of seizures and self-assessment of improvement. safety will be assessed by monitoring and recording of all of aes and serious adverse events (saes), discontinuation during 6 months treatment (patient spontaneous reporting).

Eligibility criteria:
inclusion criteria: * age ≥2y, ≤12y; * within 3 months before taking perampanel, the frequency of epileptic seizures was ≥1 time/month on average; * 1-3 kinds of aeds have been used, and the optimal dose and course of treatment have been reached, but the effect is not good. perampanel is used as an additional treatment. exclusion criteria: * patients who have participated in other researches on antiepileptic drugs or medical devices; * inaccurate or unreliable clinical records according to the judgment of participating doctors; * when the database is closed, the expected follow-up time is less than 6 months.

Keywords: epilepsy perampanel
impact of reactogenicity of the 2024-2025 covid-19 vaccines on health care workers and first responders in the united states

Conditions: COVID-19; Vaccine-Preventable Diseases; SARS CoV 2 Infection

Summary: to assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 novavax covid-19 vaccine as compared with those receiving an updated 2024-25 pfizer-biontech mrna covid-19 vaccine

this is a prospective interventional study of health care workers (hcw) and first responders (fr) receiving an updated 2024-25 covid-19 vaccination at the university of utah (ut). participants can choose which covid-19 vaccine type they would like to receive from the study team. for this study, health care workers and first responders are defined as anyone having direct face-to-face contact, defined as being within 3 feet, or about an arm's length, with patients as part of their full-time or part-time (greater than or equal to 20 hours per week) job responsibilities. approximately 660 health care workers and first responders from salt lake city, utah and surrounding areas will be enrolled into the study. this study will only enroll participants who intend to get an updated 2024-25 covid-19 vaccine during fall/winter 2024-25 sars-cov-2 virus circulation. eligible participants will choose their desired vaccine type (protein subunit: novavax, or mrna: pfizer). study vaccinators will then administer the chosen vaccine. following vaccination, study participants will receive a post vaccination questionnaire 48-hours after vaccine administration. self-reported information on systemic and local reactogenicity symptoms, socio-demographics, occupational history, medical history, covid-19 and flu vaccine history, and impact on daily activities and work will be collected through the post vaccination questionnaire.

Eligibility criteria:
inclusion criteria: * adults aged 18 years and older who have received at least one covid-19 vaccination in the past 4 years * health care workers or first responders who have direct face-to-face contact, defined as being within 3 feet, or about an arm's length, with patients as part of their full-time or part-time (greater than or equal to 20 hours per week) job responsibilities * intends to receive a dose of the updated 2024-25 covid-19 vaccine * able to understand and provide informed consent * comfortable reading and responding to text messages and emails sent in english or having an interpreter assist them * able and willing to comply with all study requirements * access to a smartphone, tablet, or computer to complete the consent, screener and study questionnaires exclusion criteria: * ongoing participation in other vaccine or investigational product trials within 90 days of study enrollment * history of self-reported severe allergic reaction to prior covid-19 vaccine * receipt of covid-19 vaccine within 60 days of enrollment * plans to receive additional vaccines within 7 days after the vaccination visit for study enrollment. (co-administered vaccinations at time or day of covid-19 vaccination are permissible)

Keywords: covid-19